The global neurodegenerative drugs market is poised for robust growth, driven by the increasing prevalence of conditions such as Alzheimer’s, Parkinson’s, and multiple sclerosis, coupled with intensified R&D and supportive healthcare initiatives. According to a new report by Allied Market Research, the market generated $36.27 billion in 2021 and is projected to reach $74.80 billion by 2031, growing at a CAGR of 7.5% during the forecast period.
Key Growth Drivers
The following factors are shaping the expansion of this vital pharmaceutical sector:
🧠 Rising incidence of neurodegenerative disorders, especially among the aging population
🏥 Government and non-government support programs to improve access and treatment options
💊 Expected launch of new therapeutic drugs targeting specific neurological pathways
🔬 Increased investment in R&D to overcome treatment gaps and discover disease-modifying therapies
However, challenges such as the complexity of drug development and high failure rates in clinical trials may temper growth. Still, continued scientific innovation is expected to unlock new market opportunities.
Segmental Analysis
💊 By Drug Class:
Immunomodulators dominated the market in 2021, accounting for over 40% of global revenue. These drugs are essential in managing autoimmune-based neurological disorders like multiple sclerosis.
Decarboxylase inhibitors are expected to witness the fastest growth with a CAGR of 11.1%, due to their increasing adoption in managing Parkinson’s disease symptoms effectively.
🧾 By Indication:
Multiple sclerosis (MS) held the largest market share in 2021, capturing more than 60% of the total revenue. MS prevalence is increasing, particularly among aging populations in developed regions.
Parkinson’s disease is projected to register the highest CAGR of 9.1% due to rising incidence and a strong drug pipeline targeting early-stage symptoms and disease progression.
🛒 By Distribution Channel:
Drug stores & retail pharmacies were the dominant segment, contributing nearly 60% of the revenue. Their accessibility and growing number of outlets drive this trend.
Online providers are forecasted to grow at a CAGR of 10.0%, as digital health adoption rises, along with discounts and home delivery services for neuro drugs.
Regional Outlook
🌎 North America: Market Leader
Held over two-fifths of the global revenue in 2021.
Growth is supported by:
High prevalence of neurodegenerative diseases
Robust pharmaceutical infrastructure
Favorable reimbursement policies
Presence of major market players
🌏 Asia-Pacific: Fastest-Growing Region
Expected to grow at a CAGR of 9.2% from 2022 to 2031.
Growth drivers include:
Expanding healthcare access
Growing elderly population
Government initiatives targeting neurological disorders
Market Snapshot
| Parameter | Details |
|---|---|
| Market Size (2021) | $36.27 Billion |
| Market Forecast (2031) | $74.80 Billion |
| CAGR (2022–2031) | 7.5% |
| Leading Drug Class | Immunomodulators |
| Fastest-Growing Drug Class | Decarboxylase Inhibitors (11.1%) |
| Leading Indication | Multiple Sclerosis |
| Fastest-Growing Indication | Parkinson’s Disease (9.1%) |
| Leading Region | North America |
| Fastest-Growing Region | Asia-Pacific (9.2%) |
Key Players and Competitive Landscape
Top companies are strengthening their market positions through collaborations, product launches, acquisitions, and regulatory approvals:
Novartis AG
AbbVie Inc.
F. Hoffmann-La Roche Ltd.
Teva Pharmaceutical Industries Ltd.
Sanofi
Orion Corporation
Sun Pharmaceutical Industries Ltd.
UCB S.A.
Viatris Inc.
Biogen
These players are focusing on neuroinflammation research, disease-modifying therapies, and biomarker-based treatments to improve patient outcomes and gain a competitive edge.
Conclusion
The neurodegenerative drugs market stands at the forefront of pharmaceutical innovation. As the burden of neurological diseases escalates worldwide, the demand for targeted, effective, and accessible treatments will continue to drive significant investment and research.
With advancements in biotechnology, neurogenomics, and digital diagnostics, the next decade is set to witness transformative breakthroughs in how we treat and manage neurodegenerative diseases.
For Purchase Inquiry- https://www.alliedmarketresearch.com/purchase-enquiry/13582
